| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 22,471 | - |
| Interest income | 21,119 | - |
| Personnel expense | 30,415 | - |
| External r&d expense | 62,979 | - |
| Manufacturing expense | 13,321 | - |
| Regulatory expense | 3,134 | - |
| Commercial programs | 15,192 | - |
| General and administrative expense | 11,386 | - |
| Depreciation and amortization | 345 | - |
| Segment adjusted loss before tax | -93,182 | - |
| Share-based compensation expense | 45,402 | - |
| Change in fair value - derivatives | 3,448 | - |
| Loss on disposal of property, plant and equipment | -1 | - |
| Foreign exchange gains/(losses) | 13,137 | - |
| Loss for the period | -128,896 | -56,891 |
| Depreciation and amortization | 161 | 97 |
| Non-cash rent expense | 3 | 3 |
| Fair value change - derivative earnout and warrants | 3,448 | -20,344 |
| Loss on disposal of property, plant and equipment | -1 | - |
| Foreign exchange (gains)/losses | 13,137 | 12,919 |
| Amortization of premium/discount on available-for-sale debt securities | -1,381 | -985 |
| Share-based compensation | 45,402 | 30,392 |
| Changes in prepayments and other receivables | 3,216 | 5,830 |
| Changes in accounts payable | -409 | 1,860 |
| Changes in accrued expenses and other current liabilities | -2,876 | -3,514 |
| Changes in deferred revenue | -6,008 | -6,008 |
| Net cash used in operating activities | -106,908 | -74,139 |
| Maturities of available-for-sale debt securities | - | 37,163 |
| Purchase of property, plant and equipment, including internal use software | 146 | 104 |
| Maturities of marketable securities | 71,563 | - |
| Purchases of available-for-sale debt securities | - | 193,340 |
| Purchases of marketable securities | 225,192 | - |
| Net cash used in investing activities | -153,775 | -156,281 |
| Transaction costs on issue of ordinary shares and pre-funded warrants-December2024Offering | 1,586 | 1,586 |
| Proceeds from exercise of warrants | 458 | 184 |
| Proceeds from exercise of options | 16,964 | 11,346 |
| Net cash provided by financing activities | 15,836 | 9,944 |
| Net change in cash, cash equivalents and restricted cash | -244,847 | -220,476 |
| Effect of exchange rate changes on cash | 12,819 | - |
| Cash and cash equivalents at beginning of period | 771,743 | - |
| Cash and cash equivalents at end of period | 539,715 | - |
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)